Effects of Needle and Catheter Size on Commercially Available Ultrasound Contrast Agents
Effects of Needle and Catheter Size on Commercially Available Ultrasound Contrast Agents
复制标题
DOI：
10.7863/ultra.14.11008
复制
发表时间：
2015-11-01
影响因子：
2.3
通讯作者：
Forsberg, Flemming
中科院分区：
文献类型：
--
作者：
Eisenbrey, John R.;Daecher, Annemarie;Forsberg, Flemming
目的探讨4种市售超声造影剂（UCA）对超声造影剂（UCA）增强及浓度的影响。方法：对definity （Lantheus Medical Imaging, North Billerica， MA）、Optison （GE Healthcare, Princeton， NJ）、SonoVue （Bracco SA, Geneva, Switzerland）和Sonazoid （GE Healthcare, Oslo, Norway）进行研究。通过1毫升注射器（BD, Franklin Lakes， NJ）将UCA注射到3路旋塞（Smith Medical, Dublin， OH）中，并通过连接到16、18、20、22或24号导管（BD）或18、20、21或25号针头（BD）的18厘米输注延长管冲洗10毫升生理盐水。体外增强在流动幻影中进行测定（ATS实验室，Bridgeport， CT），微泡浓度使用LSRII流式细胞仪进行测定（BD Biosciences, San Jose， CA）。结果：当通过25号针给药时，所有4个uca的强化和微泡浓度均显著降低（P < 0.001）。SonoVue和Sonazoid在所有导管尺寸和18- 21号针头之间的增强或浓度没有统计学上的显著差异。通过24号导管给药的确定性和选择性导致明显的增强丧失（P < 0.02），尽管这些差异在流式细胞术上不显着。结论：商用UCA在临床场景中可以使用小于20号的导管或针头，尽管最小允许尺寸似乎是针对UCA的。
Objectives-To investigate effects of needle and catheter size on in vitro ultrasound contrast agent (UCA) enhancement and concentrations using 4 commercially available UCAs.Methods-Definity (Lantheus Medical Imaging, North Billerica, MA), Optison (GE Healthcare, Princeton, NJ), SonoVue (Bracco SA, Geneva, Switzerland), and Sonazoid (GE Healthcare, Oslo, Norway) were investigated. The UCA was injected via a 1-mL syringe (BD, Franklin Lakes, NJ) into a 3-way stopcock (Smith Medical, Dublin, OH) and flushed with 10 mL of saline through an 18-cm infusion extension tube connected to either a 16-, 18-, 20-, 22-, or 24-gauge catheter (BD) or an 18-, 20-, 21-, or 25-gauge needle (BD). In vitro enhancement was determined in a flow phantom (ATS Laboratories, Bridgeport, CT), and microbubble concentrations were determined using an LSRII flow cytometer (BD Biosciences, San Jose, CA).Results-Significant decreases in enhancement and microbubble concentrations were observed for all 4 UCAs (P < .001) when administration was performed through a 25-gauge needle. No statistically significant differences in enhancement or concentrations were observed between all catheter sizes and 18- to 21-gauge needles for SonoVue and Sonazoid. Definity and Optison administration through a 24-gauge catheter resulted in a significant loss of enhancement (P < .02), although these differences were not significant on flow cytometry.Conclusions-Administration of commercial UCAs in a clinical scenario is possible with catheters or needles smaller than 20 gauge, although the minimal allowable size appears to be UCA specific.